BOEHRINGER Ingelheim has announced that it will be releasing research data demonstrating that its adalimumab biosimilar candidate delivers the same clinical benefits and safety profile as the comparator AbbVie's Humira, in a presentation at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid.
"If approved by regulatory authorities it will increase the treatment options for patients with autoimmune diseases, while contributing to the long-term sustainability of healthcare systems," said Karsten Kissel, head of Global Medical Affairs Biosimilars at Boehringer Ingelheim.
"These data, which complete our biosimilarity assessment, are currently under review by regulatory authorities along with an extensive package of non-clinical and clinical data that make up the total body of evidence required to register a biosimilar."
Humira is widely approved globally for treatment of multiple chronic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis, disorders that collectively affect the lives of 5-10% of the world population.
CLICK HERE for more detail.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Jun 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Jun 17
